Telemedicine: A Temporary Fix or a Lasting Solution?
Telemedicine solutions have seen a rise in adoption and normalisation since the COVID-19 pandemic. Global funding for Telemedicine ventures across the world grew by 36%, with the United States contributing the most and APAC following close. The whole Telemedicine ecosystem seems to be flourishing, yet some believe this to be a knee-jerk reaction. Will Telemedicine be a permanent norm in healthcare? Join us as we track its development and challenges in future transformation in a conversation with leading industry experts.June 21 | 4.00 PM SGT
Remote Patient Monitoring: The Unstoppable Wave of New Care Models
With the advent of remote patient monitoring, innovators are piloting a myriad of new care models. Be it in the prevention of hospital re-admissions or reduction in unplanned visits to the Emergency Room; the mandate is clear: broaden access to care and intervene to provide the best patient outcomes. Join us for the third instalment of The Records by Novartis BIOME and Galen Growth as we explore perspectives from the healthcare system, industry and the HealthTech ecosystem.September 23 | 4.00 PM SGT
What you will get:
- Additional insights from Galen Growth’s Remote Patient Monitoring report;
- A better understanding of the Remote Patient Monitoring ecosystem;
- Real-world experience and cases;
- 25% off the Remote Patient Monitoring report when you attend.
Speakers
Dr. Valerie Teo Head of Kallang Polyclinic, National Healthcare Group Polyclinics
Amrish Nair Co-Founder & CEO, Biorithm
Dr. Ronald Ling CEO, ConnectedHealth
Jonathan Tan Head of Patient Access, Novartis Asia
Ana Kollcaku Innovation Lead, Galen Growth
Speakers
Dr. Valerie Teo Head of National Healthcare Group Polyclinics, Kallang Polyclinic
Amrish Nair Co-Founder & CEO, Biorithm
Dr. Ronald Ling CEO, ConnectedHealth
Jonathan Tan Head of Patient Access, Novartis Asia-Pacific Middle East & Africa
Ana Kollcaku Innovation Lead, Galen Growth
Moderators
Dr. Hong-Ling Xue Asia Pacific Medical Director, Solid Tumors, Novartis Oncology
Helene Champoux COO, Galen Growth